www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the
Financial and Operating Highlights * ไม่รวมต้นทุนค่าเสื่อมราคาและค่าตัดจ าหน่าย Operating highlight in Q4/2018 and 2018 Q4/17 Q3/18 Q4/18 Change +/(-) 2017 2018 Change +/(-) (THB million) QoQ YoY YoY
fulfill such commitments. C. Trend Information 1. Indicate the facts and circumstances surrounding known material trends and uncertainties. 2. Indicate the potential impact of currently known trends, events
Highlights Q2/2019 Q1/2020 Q2/2020 Change +/- 6M/2019 6M/2020 Change +/- (Unit: THB million) %YoY %QoQ %YoY Revenue from sale of goods 2,253.8 2,076.2 1,746.3 -22.5% -15.9% 4,553.5 3,822.5 -16.1% Revenue from
profit (loss) 267 114 153 134.0% EPS (THB) 0.316 0.135 0.181 134.0% Change Major Developments in 4Q17 The SEC approved the issuance and offering for sale of 409.4 million DREIT trust units as listed
the following matters: 1) The Rational and Necessity to Increase Capital: Recently, retail business trend is decelerate due to the continuously decreasing of economic status and consumption product
the improving trend with total net addition of 522,200, 66% of which was from prepaid. Price- plan rebalancing focusing on offering full 4G speed and increasing 4G adoption to 59% resulted in mobile
distribution 234 351 118 50.4 749 957 208 27.8 Others 23 18 (5) (21.8) 38 43 5 14.3 Total 3,627 3,862 235 6.5 10,582 10,976 394 3.7 For the 3-month period ended Change For the 9-month period ended Change
summarized as follows: Consolidated FS Quarter 1/2019 Quarter 1/2020 Change MB. % MB. % MB. % Revenue from contracts with customers 1,943.6 70.9% 1,714.0 64.3% -229.6 -11.8% Interest income from loans from the